1 study found for:    CLBH589BUS48T
Show Display Options
Rank Status Study
1 Unknown  Phase I Study of Panobinostat + Bortezomib for Relapsed and/or Refractory Mantle Cell Lymphoma (MCL)
Condition: Mantle Cell Lymphoma
Interventions: Drug: Panobinostat;   Drug: Bortezomib

Indicates status has not been verified in more than two years